Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time
- PMID: 33796601
- PMCID: PMC7989225
- DOI: 10.1093/ofid/ofab090
Acute Symptoms of Mild to Moderate COVID-19 Are Highly Heterogeneous Across Individuals and Over Time
Abstract
Background: The symptoms of coronavirus disease 2019 (COVID-19) appear to be heterogenous, and the typical course of these symptoms is unknown. Our objectives were to characterize the common trajectories of COVID-19 symptoms and to assess how symptom course predicts other symptom changes as well as clinical deterioration.
Methods: One hundred sixty-two participants with acute COVID-19 responded to surveys up to 31 times for up to 17 days. Several statistical methods were used to characterize the temporal dynamics of these symptoms. Because 9 participants showed clinical deterioration, we explored whether these participants showed any differences in symptom profiles.
Results: Trajectories varied greatly between individuals, with many having persistently severe symptoms or developing new symptoms several days after being diagnosed. A typical trajectory was for a symptom to improve at a decremental rate, with most symptoms still persisting to some degree at the end of the reporting period. The pattern of symptoms over time suggested a fluctuating course for many patients. Participants who showed clinical deterioration were more likely to present with higher reports of severity of cough and diarrhea.
Conclusions: The course of symptoms during the initial weeks of COVID-19 is highly heterogeneous and is neither predictable nor easily characterized using typical survey methods. This has implications for clinical care and early-treatment clinical trials. Additional research is needed to determine whether the decelerating improvement pattern seen in our data is related to the phenomenon of patients reporting long-term symptoms and whether higher symptoms of diarrhea in early illness presages deterioration.
Keywords: COVID-19; cough; humans; severe acute respiratory syndrome coronavirus 2; smell; taste.
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures




Similar articles
-
Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.Trials. 2021 Apr 2;22(1):245. doi: 10.1186/s13063-021-05157-0. Trials. 2021. PMID: 33810796 Free PMC article.
-
Acute loss of smell and taste among patients with symptoms compatible with COVID-19.Dan Med J. 2020 Aug 6;67(9):A05200370. Dan Med J. 2020. PMID: 32800063
-
Symptom Diary-Based Analysis of Disease Course among Patients with Mild Coronavirus Disease, Germany, 2020.Emerg Infect Dis. 2021 May;27(5):1353-1361. doi: 10.3201/eid2705.204507. Emerg Infect Dis. 2021. PMID: 33900166 Free PMC article.
-
Universal testing for severe acute respiratory syndrome coronavirus 2 in 2 Philadelphia hospitals: carrier prevalence and symptom development over 2 weeks.Am J Obstet Gynecol MFM. 2020 Nov;2(4):100226. doi: 10.1016/j.ajogmf.2020.100226. Epub 2020 Sep 11. Am J Obstet Gynecol MFM. 2020. PMID: 32954248 Free PMC article.
-
Telephone interventions for symptom management in adults with cancer.Cochrane Database Syst Rev. 2020 Jun 2;6(6):CD007568. doi: 10.1002/14651858.CD007568.pub2. Cochrane Database Syst Rev. 2020. PMID: 32483832 Free PMC article.
Cited by
-
Predictors for reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A regularized, mixed-effects modelling approach.Front Immunol. 2023 Feb 9;14:971277. doi: 10.3389/fimmu.2023.971277. eCollection 2023. Front Immunol. 2023. PMID: 36845120 Free PMC article.
-
Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19.Cell Rep. 2022 Jun 28;39(13):111020. doi: 10.1016/j.celrep.2022.111020. Epub 2022 Jun 13. Cell Rep. 2022. PMID: 35738278 Free PMC article.
-
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.Clin Infect Dis. 2023 Apr 17;76(8):1403-1411. doi: 10.1093/cid/ciac933. Clin Infect Dis. 2023. PMID: 36477182 Free PMC article. Clinical Trial.
-
Association between use of psychotropic medications prior to SARS-COV-2 infection and trajectories of COVID-19 recovery: Findings from the prospective Predi-COVID cohort study.Front Public Health. 2023 Mar 16;11:1055440. doi: 10.3389/fpubh.2023.1055440. eCollection 2023. Front Public Health. 2023. PMID: 37006590 Free PMC article.
-
Patient-Reported Outcomes in COVID-19 Treatment with Monoclonal Antibodies Reveal Benefits in Return to Usual Activities.Infect Dis Ther. 2024 Aug;13(8):1861-1876. doi: 10.1007/s40121-024-01013-1. Epub 2024 Jul 3. Infect Dis Ther. 2024. PMID: 38961047 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Symptoms of Coronavirus. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Accessed 16 March 2021.
-
- World Health Organization. Coronavirus disease (COVID-19). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question.... Accessed 16 March 2021.
-
- Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 2020; 324:782–93. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources